Cargando…

COVID-19 convalescent plasma therapy through the lens of the third year of the pandemic

Detalles Bibliográficos
Autor principal:	Pirofski, Liise-anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633635/ https://www.ncbi.nlm.nih.gov/pubmed/36343900 http://dx.doi.org/10.1016/j.cmi.2022.10.033

Ejemplares similares

Rethinking the role of COVID-19 convalescent plasma in the critically ill
por: Casadevall, Arturo, et al.
Publicado: (2023)

Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy
por: Casadevall, Arturo, et al.
Publicado: (2020)

The Assessment of Convalescent Plasma Efficacy against COVID-19
por: Casadevall, Arturo, et al.
Publicado: (2020)

Understanding vaccine hesitancy in COVID-19
por: Trogen, Brit, et al.
Publicado: (2021)

Disease Severity and Durability of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Response: A View Through the Lens of the Second Year of the Pandemic
por: Pirofski, Liise-anne
Publicado: (2021)

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
por: Focosi, Daniele, et al.
Publicado: (2022)

Functional Antibodies in COVID-19 Convalescent Plasma
por: Herman, Jonathan D., et al.
Publicado: (2021)

Serosurveys and convalescent plasma in COVID-19
por: Pérez-Cameo, Cristina, et al.
Publicado: (2020)

Exploiting the Redundancy in the Immune System: Vaccines Can Mediate Protection by Eliciting ‘Unnatural’ Immunity
por: Casadevall, Arturo, et al.
Publicado: (2003)

Rethinking T cell immunity in oropharyngeal candidiasis
por: Pirofski, Liise-anne, et al.
Publicado: (2009)

Immune-Mediated Damage Completes the Parabola: Cryptococcus neoformans Pathogenesis Can Reflect the Outcome of a Weak or Strong Immune Response
por: Pirofski, Liise-anne, et al.
Publicado: (2017)

COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
por: Focosi, Daniele, et al.
Publicado: (2021)

Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence
por: Klassen, Stephen A., et al.
Publicado: (2021)

Use of convalescent plasma in COVID‐19 patients with immunosuppression
por: Senefeld, Jonathon W., et al.
Publicado: (2021)

COVID-19 Pandemic in India: Through the Lens of Modeling
por: Babu, Giridhara R., et al.
Publicado: (2021)

Towards characterized convalescent plasma for COVID-19: The dose matters
por: Verkerke, Hans P., et al.
Publicado: (2020)

Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy
por: Herman, Jonathan D., et al.
Publicado: (2022)

Cochrane corner: convalescent plasma or hyperimmune immunoglobulin for people with COVID-19
por: Nnaji, Chukwudi Arnest, et al.
Publicado: (2020)

The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19
por: Casadevall, Arturo, et al.
Publicado: (2021)

COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma
por: Sullivan, David, et al.
Publicado: (2023)

Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response
por: Herman, Jonathan D., et al.
Publicado: (2021)

Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework
por: Pirofski, Liise-anne, et al.
Publicado: (2020)

The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis
por: Klassen, Stephen A., et al.
Publicado: (2021)

COVID-19 Pandemic and the Convalescent Plasma Therapy: Possible Benefits and Risks
por: Noor, Rashed, et al.
Publicado: (2021)

Convalescent Plasma for Coronavirus Disease 2019: Dose is the Key
por: Yu, Jiangquan, et al.
Publicado: (2021)

The Ebola Epidemic Crystallizes the Potential of Passive Antibody Therapy for Infectious Diseases
por: Casadevall, Arturo, et al.
Publicado: (2015)

Convalescent plasma therapy in patients with COVID-19
por: Altuntas, Fevzi, et al.
Publicado: (2021)

Convalescent plasma therapy in patients with COVID-19
por: Altuntas, Fevzi, et al.
Publicado: (2021)

Challenges of Convalescent Plasma Therapy on COVID-19
por: Zhao, Qian, et al.
Publicado: (2020)

COVID-19 convalescent plasma therapy and immunodeficiency
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Using convalescent whole blood or plasma as passive immune therapy for the global war against Ebola
por: Lu, Shan
Publicado: (2014)

The medicolegal landscape through the lens of COVID-19: time for reform
por: Mehta, Arpan R, et al.
Publicado: (2020)

Emergence of ancient convalescent plasma (CP) therapy: To manage COVID-19 pandemic
por: Dassarma, Barsha, et al.
Publicado: (2021)

Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC
por: Yoon, Hyun ah, et al.
Publicado: (2020)

Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC
por: Yoon, Hyun ah, et al.
Publicado: (2021)

Is a single COVID-19 vaccine dose enough in convalescents ?
por: Focosi, Daniele, et al.
Publicado: (2021)

Virulence profile: Liise-anne Pirofski
por: Pirofski, Liise-anne
Publicado: (2017)

COVID-19 convalescent plasma
por: Tobian, Aaron A. R., et al.
Publicado: (2022)

What is the optimal usage of coronavirus disease 2019 convalescent plasma donations?
por: Focosi, Daniele, et al.
Publicado: (2021)

The importance of determining the amount of ‘therapeutic units’ before using convalescent plasma
por: Vieira, Yasmine Rangel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qd2mhoipdviuemb722r9kacobg